Allergan, the maker of the ulcerative colitis medication Asacol, is seeking to end a class action complaint filed by Asacol purchasers alleging that the manufacturer unlawfully delayed a generic version of the drug from entering the market. Allergan, a subsidiary of Warner Chilcott Ltd, is accused of replacing its patent expired medication with a newer version to delay the entry of a lower costing generic from entering the market and creating a monopoly. The district court certified a class of end-payors in this complaint. Stay tuned for more information as the case continues.
